SARS-CoV-2 research using human pluripotent stem cells and organoids.
Stem Cells Transl Med
; 10(11): 1491-1499, 2021 11.
Article
in English
| MEDLINE | ID: covidwho-1321718
ABSTRACT
Experimental cell models are indispensable for clarifying the pathophysiology of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and for developing therapeutic agents. To recapitulate the symptoms and drug response of COVID-19 patients in vitro, SARS-CoV-2 studies using physiologically relevant human embryonic stem (ES)/induced pluripotent stem (iPS) cell-derived somatic cells and organoids are ongoing. These cells and organoids have been used to show that SARS-CoV-2 can infect and damage various organs including the lung, heart, brain, intestinal tract, kidney, and pancreas. They are also being used to develop COVID-19 therapeutic agents, including evaluation of their antiviral efficacy and safety. The relationship between COVID-19 aggravation and human genetic backgrounds has been investigated using genetically modified ES/iPS cells and patient-derived iPS cells. This review summarizes the latest results and issues of SARS-CoV-2 research using human ES/iPS cell-derived somatic cells and organoids.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Organoids
/
Human Embryonic Stem Cells
/
SARS-CoV-2
/
COVID-19
Type of study:
Experimental Studies
Limits:
Humans
Language:
English
Journal:
Stem Cells Transl Med
Year:
2021
Document Type:
Article
Affiliation country:
Sctm.21-0183
Similar
MEDLINE
...
LILACS
LIS